<DOC>
	<DOCNO>NCT00002006</DOCNO>
	<brief_summary>To assess safety efficacy subcutaneously administer sargramostim ( granulocyte-macrophage colony-stimulating factor ; GM-CSF ) increase maintain neutrophil count HIV-infected adult develop neutropenia result receive antiretroviral agent , zidovudine ( AZT ) . To assess safety efficacy subcutaneously administer GM-CSF increase maintain neutrophil count HIV-infected adult pre-existing neutropenia high risk develop hematologic intolerance receive antiretroviral agent , AZT , first time . To assess potential therapeutic benefit concomitant GM-CSF AZT natural history HIV infection associate infectious complication .</brief_summary>
	<brief_title>A Phase I/II Pilot Study Simultaneously Administered Rhu GM-CSF ( CHO Cell ) Azidothymidine ( AZT ) Patients With Severe HIV Infection Leukopenia : Pharmacokinetics Feasibility</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Leukopenia</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Treatment : Allowed : Minimal local irradiation tumor . Patients must : Diagnosis AIDS AIDS relate complex ( ARC ) . Neutropenia , due either zidovudine ( AZT ) HIV infection . Life expectancy = &gt; 6 month . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Significant malabsorption define great 10 percent weight loss one following : Serum carotene le 75 IU/ml . Vitamin A level less 75 IU/ml . More 4 foulsmelling greasy stool per day . Other criteria malabsorption . Kaposi 's sarcoma ( KS ) tumor likely require specific antitumor therapy study , minimal local irradiation . Active , lifethreatening infection bacterial , viral , fungal , protozoan pathogen fever 39 degree C within 10 day study entry , unless apparent fever due severe underlie infection . Concurrent Medication : Excluded within 4 week study entry : Any investigational drug . Immunomodulating agent . Hormonal therapy . Cytolytic chemotherapeutic agent . Antiretroviral agent zidovudine ( AZT ) . Excluded within 4 month study entry : Suramin . Excluded within 3 month study entry : Ribavirin . Patients follow exclude : Significant malabsorption . Tumor likely require specific antitumor therapy study . Other significant medical problem condition specify Patient Exclusion CoExisting Conditions . Uncorrected nutritional deficiency may contribute neutropenia . Hypersensitivity zidovudine ( AZT ) nucleoside analogs . Profound dementia alter mental status would prohibit give informed consent . Prior Treatment : Excluded within 1 month study entry : Transfusion . Excluded within 4 week study entry : Radiation therapy great 100 cm2 body area . Current drug alcohol abuse . Unprotected sexual behavior activity might introduce new inoculation HIV study . Patients must willing refrain unprotected sexual activity might introduce new inoculum HIV study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1990</verification_date>
	<keyword>Neutropenia</keyword>
	<keyword>Drug Interactions</keyword>
	<keyword>Granulocyte-Macrophage Colony-Stimulating Factor</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>